title: HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
authors.affiliation: 1 Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, PA.
authors.forename: K Rajender
authors.initials: KR
authors.lastname: Reddy
authors.forename: Amina
authors.initials: A
authors.lastname: Wirjosemito
authors.forename: Tanya M
authors.initials: TM
authors.lastname: Pavri
authors.forename: Lorie
authors.initials: L
authors.lastname: Sinese
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D002219:Carbamates; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D053306:Hyper-IgM Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology*; D007093:Imidazoles / Q000008:administration & dosage*; D007075:Immunoglobulin M / Q000276:immunology; D016898:Interferon-alpha / Q000008:administration & dosage*; D016031:Liver Transplantation; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives; D011759:Pyrrolidines; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage*; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D007075:Immunoglobulin M; D016898:Interferon-alpha; D011759:Pyrrolidines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; D014633:Valine; C549273:daclatasvir; C100416:peginterferon alfa-2a